Global Brain Tumor Diagnosis and Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Brain Tumor Diagnosis and Treatment Market Analysis

The brain tumor diagnosis and treatment market is experiencing substantial growth driven by advancements in biotechnology and molecular research. Developments in this field includes the introduction of innovative cell lysis technologies that offer higher efficiency and better preservation of cellular components. Companies are now focusing on developing more refined and automated systems that integrate seamlessly into various research workflows. For instance, the introduction of microfluidic devices and acoustic lysis systems has revolutionized how researchers handle and process cell samples, providing precise control over the lysis process and minimizing sample loss. Additionally, advancements in reagent formulations and the development of novel consumables are enhancing the versatility and effectiveness of brain tumor diagnosis and treatment techniques. The market is also benefiting from increased investments in research and development by pharmaceutical and biotechnology companies, as well as a growing emphasis on personalized medicine and regenerative therapies.

Brain Tumor Diagnosis and Treatment Market Size

The global brain tumor diagnosis and treatment market size was valued at USD 618.28  million in 2023 and is projected to reach USD 1,129.23 million by 2031, with a CAGR of  7.82% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Brain Tumor Diagnosis and Treatment Market Trends

“Rising Adoption of Enzymatic Cell Dissociation Methods”

Le marché du diagnostic et du traitement des tumeurs cérébrales est en pleine croissance grâce aux progrès des technologies d’imagerie et de la médecine personnalisée. L’une des principales tendances du marché est l’adoption croissante de techniques de biopsie liquide pour un diagnostic précoce et non invasif. Les biopsies liquides, qui analysent l’ADN tumoral circulant (ADNtc) dans la circulation sanguine, offrent une alternative moins invasive aux biopsies tissulaires traditionnelles. Par exemple, des entreprises telles que Biocept ont développé des plateformes de biopsie liquide qui détectent les biomarqueurs des tumeurs cérébrales, permettant un diagnostic plus précoce et une meilleure planification du traitement. Cette technologie est particulièrement bénéfique pour surveiller la progression de la tumeur et la réponse au traitement en temps réel. De plus, les progrès des thérapies ciblées, telles que l’immunothérapie et la radiothérapie de précision, offrent des options de traitement plus efficaces avec moins d’effets secondaires. Ces innovations, combinées à l’incidence croissante des tumeurs cérébrales et à la demande d’outils de diagnostic peu invasifs, stimulent la croissance du marché du diagnostic et du traitement des tumeurs cérébrales, améliorant les résultats des patients et renforçant le potentiel du marché.

Portée du rapport et segmentation du marché du diagnostic et du traitement des tumeurs cérébrales

Définition du marché du diagnostic et du traitement des tumeurs cérébrales

Le diagnostic et le traitement des tumeurs cérébrales font référence aux processus médicaux utilisés pour identifier et gérer les croissances anormales de cellules dans le cerveau. Le diagnostic implique généralement des technologies d'imagerie telles que l'IRM (imagerie par résonance magnétique) et la tomodensitométrie (tomodensitométrie) pour détecter les tumeurs, ainsi que des techniques telles que la biopsie, où un échantillon de la tumeur est examiné. Des méthodes émergentes telles que les biopsies liquides et les diagnostics moléculaires sont également utilisées pour la détection non invasive. Le traitement englobe diverses approches en fonction du type, de la localisation et du stade de la tumeur, notamment la chirurgie, la radiothérapie, la chimiothérapie, la thérapie ciblée et l'immunothérapie. L'objectif est de retirer ou de réduire la tumeur tout en minimisant les dommages aux tissus cérébraux sains et en préservant la fonction neurologique.

Dynamique du marché du diagnostic et du traitement des tumeurs cérébrales

Conducteurs

• Incidence croissante des tumeurs cérébrales

L'augmentation de l'incidence des tumeurs cérébrales stimule considérablement le marché du diagnostic et du traitement des tumeurs cérébrales. Selon le rapport Global Cancer Burden and Strategies for Cancer Control (GLOBOCAN) 2020, il y a eu 19,3 millions de nouveaux cas de cancer dans le monde en 2020, avec près de 10,0 millions de décès attribués au cancer. La prévalence croissante est influencée par des facteurs tels que l'exposition environnementale aux rayonnements et aux polluants chimiques, ainsi que par les prédispositions génétiques. Alors que les cas de tumeurs cérébrales continuent d'augmenter, la demande d'outils de diagnostic avancés, tels que l'imagerie haute résolution et les diagnostics moléculaires, augmente, parallèlement à un besoin croissant d'options de traitement innovantes, notamment des thérapies ciblées et des immunothérapies. L'augmentation de l'incidence alimente directement la nécessité de poursuivre le développement et l'adoption de solutions de pointe, stimulant ainsi la croissance du marché du diagnostic et du traitement des tumeurs cérébrales.

• Programmes de sensibilisation et de dépistage en pleine croissance

Growing awareness and screening programs are significantly impacting the early detection and diagnosis of brain tumors, leading to increased demand for diagnostic and therapeutic solutions. Public health initiatives and educational campaigns are playing a crucial role in this shift. For instance, organizations such as the American Brain Tumor Association (ABTA) run awareness campaigns that educate public about brain tumor symptoms and the importance of early screening. Such efforts have been linked to increased participation in screening programs, such as MRI scans for individuals at higher risk or those experiencing symptoms. "Brain Tumor Awareness Month" campaign, which raises awareness about the signs of brain tumors and encourages timely medical consultation is further disseminating the awareness and screening programs. As more people become aware of the importance of early detection and seek out screening services, the demand for advanced diagnostic tools and effective treatment options rises, further propelling growth in the brain tumor diagnosis and treatment market.

Opportunities

• Advancements in Imaging Technologies

Advancements in imaging technologies are significantly enhancing the accuracy and effectiveness of brain tumor diagnosis. For instance, the development of advanced MRI techniques, such as high-field MRI and functional MRI (fMRI), offers detailed insights into brain activity and tumor morphology, improving tumor localization and characterization. Additionally, molecular imaging technologies, including positron emission tomography (PET) with radiolabeled tracers, provide valuable information on metabolic activity and tumor cell proliferation, which is crucial for assessing tumor behavior and response to treatment. Specifically, 18F-FDG PET scans have demonstrated the ability to accurately differentiate between tumor types and evaluate treatment efficacy in brain tumor patients. Such innovations not only enhance diagnostic precision but also create opportunities for companies to develop and market cutting-edge imaging solutions, meeting the growing demand for advanced diagnostic tools in the brain tumor market.

• Expansion of Targeted Therapies and Immunotherapies

The expansion of targeted therapies and immunotherapies is transforming the treatment landscape for brain tumors, providing new avenues for combating these challenging conditions. Targeted therapies focus on specific genetic mutations that drive tumor growth, offering a more tailored approach to treatment. For instance, temozolomide is a chemotherapy drug designed to target the DNA repair mechanisms unique to certain brain tumors, such as glioblastomas. Immunotherapies, such as CAR-T cell therapy, where T cells are engineered to recognize and attack tumor cells, showing potential in treating brain tumors such as glioblastoma by targeting cancer cells while minimizing damage to healthy tissue. Companies that invest in these advanced treatment options can capitalize on these innovations, meeting the rising demand for effective brain tumor therapies and improving patient outcomes. Consequently creating great opportunities in the market growth.

Restraints/Challenges

• Complexity of Brain Tumors

The complexity of brain tumors presents a significant challenge in both diagnosis and treatment, as these tumors exhibit considerable variability in their types, locations, and genetic profiles. For instance, glioblastomas, a highly aggressive type of brain tumor, differ markedly from meningiomas, which generally have a better prognosis and less aggressive behavior. Glioblastomas often have diverse genetic mutations and varying responses to treatment, necessitating highly specialized diagnostic tools such as advanced MRI imaging and genetic profiling to accurately identify and understand the tumor's characteristics. Similarly, treatment plans must be tailored to each tumor's specific genetic and molecular features, requiring a multidisciplinary approach involving neurosurgeons, oncologists, and radiologists. This complexity not only complicates the development of standardized treatment protocols but also makes it challenging to implement personalized therapies consistently. Consequently hampering the brain tumor diagnosis and treatment market.

• Limited Availability of Advanced Diagnostic and Treatment Technologies

The limited availability of advanced diagnostic and treatment technologies significantly impacts the quality of care in the brain tumor market, creating disparities between well-equipped centers and those with fewer resources. For instance, cutting-edge imaging systems such as high-field MRI scanners and PET-CT systems, which are crucial for accurate tumor localization and monitoring, are often found only in specialized centers or high-income countries. Patients in lower-income regions or less developed healthcare settings may not have access to these technologies, leading to delays in accurate diagnosis and suboptimal treatment planning. Such disparity is exemplified by the availability of novel therapeutic agents, such as targeted therapies or immunotherapies, which may only be accessible through clinical trials or in countries with advanced healthcare infrastructure.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Brain Tumor Diagnosis And Treatment Market Scope

The market is segmented on the basis of product type, product analysis, diagnosis type, treatment type, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Primary Brain Tumor
  • Meningioma
  • Gliomas
  • Astrocytomas
  • Pituitary Tumors
  • Others
• Secondary Brain Tumor

Product Analysis

• Stains and Varnishes
• Shellacs
• Lacquers
• Others

Diagnosis Type

• CT Scan
• MRI
• PET-CT Scan
• Molecular Testing
• EEG
• Others

Treatment Type

• Surgery
• Radiation Therapy
• Targeted Therapy
• Chemotherapy
• Immunotherapy

End User

• Hospitals
• Ambulatory Surgical Centers

Brain Tumor Diagnosis And Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, product analysis, diagnosis type, treatment type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the brain tumor diagnosis and treatment market, primarily due to significant research and development efforts, a high incidence of brain tumor diagnoses, and increasing awareness of treatment and management options. The region's advanced healthcare infrastructure, coupled with substantial investments in oncology research, further strengthens its dominance in this market. Additionally, growing public awareness about early diagnosis and available treatment methods contributes to the rising demand for advanced brain tumor therapies in North America.

Europe is projected to witness the highest growth rate in the brain tumor diagnosis and treatment market during the forecast period of 2024 to 2031. This growth is largely driven by government initiatives aimed at raising awareness of advanced medical technologies and improving access to cutting-edge treatments across the region. Additionally, increased investment in healthcare infrastructure and research, along with growing public awareness about early diagnosis and advanced therapies, is expected to fuel the market's expansion in Europe.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Brain Tumor Diagnosis and Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Brain Tumor Diagnosis and Treatment Market Leaders Operating in the Market Are:

• Pfizer Inc. (U.S.)
• Mayo Foundation for Medical Education and Research (MFMER) (U.S.)
• GE HealthCare (U.S.)
• AstraZeneca (U.K.)
• Merck & Co., Inc. (U.S.)
• Siemens Healthineers AG (Germany)
• Carestream Health (U.S.)
• Hitachi, Ltd. (Japan)
• Koninklijke Philips N.V. (Netherlands)
• Shimadzu Corporation (Japan)
• Canon Medical Systems (Japan)
• Eisai Co., Ltd. (Japan)
• Elekta (Sweden)
• Varian Medical Systems, Inc. (U.S.)
• FUJIFILM Corporation (Japan)
• NantOmics (U.S.)
• Hologic, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Genentech, Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)

Latest Developments in Brain Tumor Diagnosis And Treatment Market

• In March 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals, aiming to accelerate advancements in cancer treatment. This acquisition is focused on shifting away from conventional therapies like chemotherapy and radiotherapy, towards more innovative and targeted approaches that enhance patient outcomes
• In January 2024, GE HealthCare acquired MIM Software, a company specializing in AI-driven imaging and workflow solutions. This acquisition enables GE HealthCare to integrate MIM’s advanced AI-enabled tools into sectors such as oncology and neurology, enhancing diagnostic accuracy and improving treatment planning across these critical healthcare domains

SKU-60266